Publications
Detailed Information
Pluronic® F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Mi Lan | - |
dc.contributor.author | Jiang, Hu-Lin | - |
dc.contributor.author | Kang, Sang Gyun | - |
dc.contributor.author | Guo, Ding Ding | - |
dc.contributor.author | Lee, Deog Yong | - |
dc.contributor.author | Cho, Chong-Su | - |
dc.contributor.author | Yoo, Han Sang | - |
dc.date.accessioned | 2009-08-21T08:23:08Z | - |
dc.date.available | 2009-08-21T08:23:08Z | - |
dc.date.issued | 2007-04-09 | - |
dc.identifier.citation | Vaccine 2007;25: 4602-4610 | en |
dc.identifier.issn | 0264-410X | - |
dc.identifier.uri | https://hdl.handle.net/10371/7473 | - |
dc.description.abstract | We have studied a vaccine delivery system in vitro and in vivo based on chitosan microspheres (CMs) prepared in the presence of selected immunomodulators, Pluronic® block copolymer F127 (F127). The Bordetella bronchiseptica multiple antigens containing dermonecrotoxin (BBD), a virulent factor leading to atrophic rhinitis (AR) in swine was loaded in CMs/F127 or CMs alone. The microspheres, prepared using an ionic gelation process with tripolyphosphate, demonstrated release profiles that showed a greater amount of BBD being released from BBD-loaded CMs/F127 (BBD-CMs/F127). In vitro experiments using mouse alveolar macrophage cells (RAW 264.7) demonstrated that BBD-CMs/F127 have significantly higher immune-stimulating activities than controls. The highest immune-stimulating activities by the BBD-CMs/F127 using RAW 264.7 cells were mirrored in the in vivo studies following nasal administration to mice. The mice immunized with BBD-CMs/F127 showed higher BBD specific IgA antibody responses in nasal wash, saliva and serum than mice immunized with BBD-CMs alone. Protective immunity was measured by survival rate after challenge with B. bronchiseptica via the nasal cavity. The survival rate of the group treated with BBD-CMs/F127 was higher than those of other groups. These results suggested that CMs/F127 represents a novel mucosal delivery system and that F127 could enhance the delivery of BBD-CMs in the vaccination scheme. | en |
dc.description.sponsorship | This study was supported by MAFF special grants (202129-3), KRF (2006-005-J02901), BK21 and the Research Institute for Veterinary Science, Seoul National University, Korea. | en |
dc.language.iso | en | en |
dc.publisher | Elsevier | en |
dc.subject | Pluronic F127 | en |
dc.subject | Chitosan microsphere | en |
dc.subject | Bordetella bronchiseptica | en |
dc.subject | Dermonecrotoxin | en |
dc.subject | Drug delivery system | en |
dc.subject | Intranasal administration | en |
dc.title | Pluronic® F127 enhances the effect as an adjuvant of chitosan microspheres in the intranasal delivery of Bordetella bronchiseptica antigens containing dermonecrotoxin | en |
dc.type | Article | en |
dc.contributor.AlternativeAuthor | 강미란 | - |
dc.contributor.AlternativeAuthor | 강상균 | - |
dc.contributor.AlternativeAuthor | 이덕용 | - |
dc.contributor.AlternativeAuthor | 조종수 | - |
dc.contributor.AlternativeAuthor | 유한상 | - |
dc.identifier.doi | 10.1016/j.vaccine.2007.03.038 | - |
- Appears in Collections:
- Files in This Item:
- There are no files associated with this item.
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.